01/30/2024
Pharmaceutical manufacturer GlaxoSmithKline (GSK) announced that as of Jan. 1, it would no longer produce the asthma inhaler Flovent, one of the most popular preventive and maintenance treatments for asthma and pediatric asthma for decades potentially leaving patients, healthcare providers and insurers scrambling.
The amount of stress and fear this creates for patients, healthcare providers and caregivers are overwhelming. In the face of uncertainty, the team at Sonavi Labs steps in to offer hands on solutions that support the management of uncontrolled symptoms to help prevent hospitalization and death.
Sonavi Labs was formed to deploy Feelix®, the only FDA cleared, HIPAA compliant, user-friendly, Bluetooth enabled, remote monitoring platform embedded with state-of-the-art patented technology that uses clinically validated diagnostic AI software capable of detecting respiratory diseases and tracking longitudinal trends. The Feelix® system is intended to enhance remote monitoring programs and ensure care teams have the most objective clinical data to triage, treat and monitor patients. For more information, please visit our website: www.sonavilabs.com
, , , , ,